Early fatigue in cancer patients receiving pd-1/pd-l1 checkpoint inhibitors: an insight from clinical practice

HIGHLIGHTS

• who: Alessio Cortellini from the This analysis was performed within the already available "real-life" multicenter retrospective data set, where we collected clinical data of advanced cancer patients who underwent treatment with single PD-1/PD-, checkpoint inhibitors as first or subsequent line [5-7] (University of L'Aquila, Internal Review Board protocol number, approved on July, th, )Only patients with data availability regarding ir-fatigue were included in the present analysis. The aim of this analysis was to evaluate the correlations between "early ir-fatigue", "delayed ir-fatigue", and following clinical outcomes: objective response rate (ORR . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.